Table 2.

Neuropsychological test scores for all subjects ^a.

	Startup		Follow-Up		Treatment × Time Interaction b
	Active	Placebo	Active	Placebo	Active	Placebo	p Value
MMSE	27.5 ± 2.2	27.0 ± 2.1	27.1 ± 2.5	26.0 ± 3.4	−0.4 ± 1.6	−1.0 ± 1.8	0.252
gloCDR	0.5	0.5	0.38 ± 0.2	0.48 ± 0.2	−0.12 ± 0.22	−0.02 ± 0.18	0.0231
CDRsob	0.82 ± 0.45	1.04 ± 0.53	0.80 ± 0.5	1.12 ± 0.77	−0.02 ± 0.51	0.12 ± 0.79	0.583
WMS-1	7.8 ± 4.4	7.0 ± 4.5	9.1 ± 4.4	8.2 ± 5.7	1.2 ± 2.8	1.2 ± 3.1	0.591
WMS-2	5.3 ± 4.4	5.6 ± 4.6	6.7 ± 5.2	6.4 ± 6.1	1.4 ± 3.0	0.7 ± 3.0	0.975
ADAS	12.3 ± 7.4	15.5 ± 7.6	13.0 ± 8.5	15.4 ± 8.6	0.8 ± 4.4	−0.2 ± 4.7	0.320
GDS	2.5 ± 1.9	2.5 ± 2.4	2.6 ± 2.9	2.6 ± 2.1	0.1 ± 2.7	0.1 ± 2.0	0.943

^a Data are shown in mean ± Standard Deviation. ^b The change between start-up and follow-up.